Table 2.

GLP1 receptor agonist use and risk of thyroid cancer

Analysis	GLP1 receptor agonists (n=145 410)			DPP4 inhibitors (n=291 667)		Hazard ratio (95% CI)*	Rate difference (95% CI) per 10 000 person years*
	No of events	Rate per 10 000 person years*		No of events	Rate per 10 000 person years*
Main analysis (any thyroid cancer)	76	1.33		184	1.46	0.93 (0.66 to 1.31)	−0.13 (−0.61 to 0.36)
Subtypes of thyroid cancer
Papillary	53	0.93		114	1.04	0.92 (0.61 to 1.39)	−0.11 (−0.53 to 0.31)
Follicular	16	0.28		47	0.27	0.99 (0.47 to 2.08)	0.01 (−0.19 to 0.21)
Medullary	4	0.07		11	0.07	1.19 (0.37 to 3.86)	0.00 (−0.09 to 0.09)
Other	5	0.09		15	0.05	1.51 (0.44 to 5.20)	0.04 (−0.05 to 0.12)

Total crude number of person years in main analysis was 569 538 in the GLP1 receptor agonist group and 1 580 409 in the DPP4 inhibitor group.

CI=confidence interval; DPP4=dipeptidyl peptidase 4; GLP1=glucagon-like peptide 1.

^*Rates, rate differences, and hazard ratios adjusted for all variables shown in table 1 using propensity score fine stratification weighting.